Copenhagen, October 03, 2022: SNIPR Biome ApS (“SNIPR” or “the Company”), a company pioneering CRISPR-based microbial gene therapy, announces that its patent portfolio covering the use of CRISPR/Cas ...

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Copenhagen, April 22 2024: SNIPR Biome ApS (“SNIPR”), ...

SNIPR Biome has said its CRISPR therapeutic targeting a problem bacterial pathogen has shown proof-of-concept in a phase 1 trial, raising hopes of a new way to treat resistant infections as ...

Snipr Biome has raised (PDF) $50 million (€43 million, DKK320 million) to take CRISPR-based microbiome drugs into clinical trials. The Danish biotech is using CRISPR/Cas to selectively target and kill ...

Many cancer treatments—including chemotherapies and engineered immune cells—can result in side effects. This is in large part because the treatments affect healthy cells in the body as well as ...

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- SNIPR BIOME ApS ("SNIPR” or "the Company”), a clinical stage biotech company pioneering CRISPR-based therapies, today announces grant of patent ...

Patent issuance adds to SNIPR's extensive intellectual property portfolio, comprising more than 60 granted worldwide patents, including in the USA and Europe Patent covers the use of killing of ...

The University of Texas MD Anderson Cancer Center and SNIPR BIOME today announced a strategic collaboration to advance new CRISPR-based microbiome therapeutics to reduce immune-related adverse events ...

It is well to recall that the battle over inventorship and thus ownership of CRISPR technology is not limited to the parties in the various interferences surrounding the Doudna and Zhang patents and ...

COPENHAGEN, Denmark, April 20, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, today announced dosing of the first human subjects in its phase ...

SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes Copenhagen, October 03, 2022: SNIPR Biome ApS (“SNIPR” or “the Company”), a company ...